Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

787.00 -2.32 (-0.29%)
Streaming Delayed Price Updated: 10:33 AM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
22 23 24 25 26 27 28 29 30
...
99 100 Next >
3 Must-Buy Stocks Before the Third Quarter
Pounce on these three must buy-stocks before the third quarter starts, and take home solid gains as they soar on an improved economy. 
Via InvestorPlace
Is Eli Lilly the Best Pharmaceutical Stock for You?
Eli Lilly is serving a market that may reach $100 billion. 
Via The Motley Fool
Jim Cramer Sees Eli Lilly As More Than A 'One-Trick Pony' After FDA Advisors Back Its Alzheimer's Drug: 'It's Ultimately Headed To A Trillion Dollar Valuation'
Jim Cramer has expressed his confidence in Eli Lilly and Co, citing the company's diverse drug portfolio and the recent endorsement of its Alzheimer's treatment by FDA advisors. 
Via Benzinga
Exposures Product Safety
Eli Lilly Has Likely Blockbuster Drug, Elevated To Stock Spotlight: Joins These Names Just Added To IBD's Top Screens
Eli Lilly hit another all-time high Tuesday. It's seeing gains in large part because it's a leader in drugs to treat obesity and diabetes 
Via Investor's Business Daily
Eli Lilly's Donanemab Gains Favorable FDA Advisory Verdict, Boosting Stock Potential, Says BofA Analyst
Eli Lilly's donanemab for Alzheimer's disease garners positive FDA committee verdict, prompting analyst's bullish outlook amid comparisons to Biogen's Leqembi. 
Via Benzinga
Exposures Product Safety
Unpacking the Latest Options Trading Trends in Eli Lilly and Co
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Eli Lilly Drags Alzheimer's Stocks Prothena, Eisai Lower Despite FDA Win
An FDA panel unanimously backed Eli Lilly's Alzheimer's drug, but shares of Lilly and its rivals fell Tuesday. 
Via Investor's Business Daily
Exposures Product Safety
Why Are Stocks Down Today?
Stocks are down today and investors seeking out the answers to why that's the case will want to stick around for our Tuesday coverage. 
Via InvestorPlace
Eli Lilly Stock Hits New 52-Week High as FDA Panel Recommends Alzheimer’s Drug
Eli Lilly stock is up on Tuesday as investors in LLY celebrate an FDA panel putting its support behind the company's Alzheimer's drug. 
Via InvestorPlace
Exposures Product Safety
Top 4 Health Care Stocks That May Keep You Up At Night This Month
Via Benzinga
Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D for Developing Innovative Drugs Rises
EQNX::TICKER_START (NASDAQ:TLSA),(NYSE:LLY),(OTCQX:RHHBY),(NASDAQ:BIIB),(NASDAQ:TGTX) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures Product Safety
Why Is Eli Lilly Stock Trading Higher Premarket Tuesday?
Shares of Eli Lilly surged as an FDA advisory committee endorsed donanemab, an Alzheimer's treatment shown to significantly impact early-stage patients. The drug's benefits outstripped risks, setting... 
Via Benzinga
Exposures Product Safety
Eli Lilly Hits an All-Time High: Is the Soaring Pharma Stock Still a Buy?
The world's biggest healthcare company might become even larger. 
Via The Motley Fool
Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D for Developing Innovative Drugs Rises
From FN Media Group LLC
Via GlobeNewswire
Structure Therapeutics Stock Could Rocket 87% Higher, According to 1 Wall Street Analyst. Is It Time to Buy?
Analysts who follow the start-up drugmaker think its stock has a chance to soar, but that doesn't mean it's right for you. 
Via The Motley Fool
Apple, Meta, Celsius, Eli Lilly, Tesla: Why These 5 Stocks Are On Investors' Radars Today
On Monday, major U.S. indices closed positively, with the Dow Jones Industrial Average rising by 0.2% to 38,868.04. 
Via Benzinga
Topics Stocks
Exposures US Equities
7 Over-Hyped Stocks to Sell Before They Plunge: June Edition
Although these popular names may be hot now, soon the market could agree that they are over-estimated stocks to sell. 
Via InvestorPlace
Eli Lilly Rises Again, As FDA Panel Mulls Biogen-Rivaling Alzheimer's Drug
The FDA isn't bound by the committee's recommendation, but often follows it. 
Via Investor's Business Daily
Exposures Product Safety
What's Happening With Eli Lilly Shares On Monday?
Eli Lilly reports detailed results from the SYNERGY-NASH phase 2 study. The trial, involving 190 patients with and without type 2 diabetes, showed tirzepatide met the primary endpoint, achieving MASH... 
Via Benzinga
Abbott Snags U.S. Clearance To Enter The Obesity Arena, Rivaling Dexcom
The FDA clearance for two new CGMs puts Abbott on track to rival Dexcom's new Stelo device. 
Via Investor's Business Daily
Exposures Product Safety
7 Blue-Chip Stocks to Add to Your June Buy List
There are huge advantages to having blue-chip stocks in your portfolio, particularly when the stock market is on a roll. Consider these. 
Via InvestorPlace
The Company Behind Mounjaro and Zepbound Is Sponsoring Caitlin Clark. Should You Buy the Stock?
One of the most lucrative sports sponsorship opportunities is jersey patches, and one leading pharmaceutical company may have just struck gold. 
Via The Motley Fool
Profiting from the Crowd: 3 Stocks Set to Surge on Retail Investor Enthusiasm
You can use the wisdom of crowds and their fear and greed motives to profit from these three stocks to buy with plenty of room to run. 
Via InvestorPlace
SPDR ETF Report For Friday, June 7
In this video, Ira Epstein reviews the day's trading in various SPDR-ETF markets for the trading day that ended, Friday, June 7. 
Via Talk Markets
Topics ETFs
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Stocks Choppy As 'Higher for Longer' Fed Rhetoric Weighs
Stocks are out of their morning rut, but trading is still choppy to end the week. 
Via Talk Markets
Topics Economy
Exposures Interest Rates
Over 10,000 Lawsuits In Novo Nordisk's Ozempic Case Assigned to New Judge
Judge Karen Marston takes over the high-profile Ozempic litigation involving over 10,000 lawsuits. Here's the latest. 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Wall Street Reacts To Hot Jobs Report: Stocks Swing As Traders Abandon July Rate Cut Hopes
May labor market report: strong job gains and wage growth, reduces chances of rate cut. Interest-rate sensitive sectors underperform. Top risers: APD, URI, LLY, HUBB, ADP. Top losers: GEN, SHW, FCX,... 
Via Benzinga
Stock Market Revs To Highs On Nvidia, CrowdStrike, Yields: Weekly Review
The Nasdaq and S&P 500 hit record highs, but small caps retreated. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
< Previous 1 2
...
22 23 24 25 26 27 28 29 30
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.